CORDIS · 817109 · H2020
CLEANprocesses Gaining an in-depth understanding of the technical feasibility and commercialization potential for the cold-active amylase enzyme
Coordinator: NUNAZYMES APS (GL)
CLEANprocesses (CoLd-active Enzymes and New sustainable Processes) will analyse the technical feasibility of a cold-active amylase enzyme as well as its commercial potential in various markets. Enzymes are a key ingredient in many consumer products, such as food & drinks, textile, pharmaceuticals and detergents, and the enzyme market has become a multibillion dollar industry worldwide. For decades, it has been a goal for enzyme producers to discover truly cold-active enzymes, due to their performance at low temperature industrial processes resulting in significant reduction in energy and cost…
About Horizon 2020 (2014–2020)
Horizon 2020 was the EU's flagship research and innovation programme for 2014–2020, with a budget of around €77 billion. It bundled FP7's strands with the EIT and the Competitiveness and Innovation Programme, introduced a stronger societal-challenge orientation, and pushed the funding logic toward closer-to-market innovation. New calls closed in 2020 but funded projects continued through 2024.
Co-funding: the European Union contributes €50k toward a total project budget of €71k — a funding rate of 70%, with the remainder covered by the consortium partners. The project runs over approximately 0.5 years from 2018-06-01 to 2018-11-30.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from GL
see all →Other H2020 projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon 2020 through a Joint programme of the members of the EUROfusion consortium633053 · DE · €678.8M
- H2020 — COST at a turning point: A unique framework for pan-European ST cooperation as clear demonstration of European values681463 · BE · €178.2M
- HBP SGA3 — Human Brain Project Specific Grant Agreement 3945539 · BE · €150.0M
- COVID-19 VACCINES — PROPOSAL FOR FUNDING RESEARCH DEVELOPMENT AND MANUFACTURING OF VACCINE AGAINST COVID-19101018100 · NO · €100.0M
- UNITE4TB — ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS101007873 · NL · €92.5M
- ERA4TB — EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS853989 · ES · €89.8M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon 2020 (2014–2020) programme, under the SME-1 funding scheme.
- What is the EU contribution?
- The European Commission contributes €50k toward a total project budget of €71k.
- Which EU programme funds it?
- The project is funded under Horizon 2020 (2014–2020), call H2020-EIC-SMEInst-2018-2020.
- Who coordinates the project?
- The project is coordinated by NUNAZYMES APS (GL).
- What is the project timeline?
- The project runs from 2018-06-01 to 2018-11-30 — approximately 0.5 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 817109.